VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
← catalyst calendarNCT06874621 · readout ≤ 284 d
Sponsored by Voyager Therapeutics (industry) · VYGR — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
52estimated
Sites
23
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-03 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer's Disease (AD)
Interventions
- Drug: VY7523
- Drug: Placebo Comparator
Primary outcome
what the primary-completion date above is the date OFCharacterization of the safety and tolerability of VY7523 in participants with early AD
measured Cohorts 1 and 2: up to 6 months Cohort 3: up to 12 months
Permalink · VYGR's whole pipeline · Catalyst calendar · Every registered study · What changed